Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

  • Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1
     
  • Study also met key secondary endpoints, significantly improving failure-free survival and patient-reported symptoms1
     
  • GvHD is a serious and common complication of stem cell transplants with no widely approved treatment options for patients who do not respond to steroids2,3 …
/by

Helping clinical trial patients during a lockdown

Streets were empty in Wuhan, China. Transportation was suspended, travel restricted and social contacts reduced to a minimum. Hospitals postponed surgeries and limited routine care. While the world’s attention was focused on those infected with COVID-19 in the city earlier this year, other patients struggled to get the treatment they needed.

…
/by